Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1701641

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Mental Health
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact on the mental health of medical practitioners of withdrawing NHS Practitioner Health services for new applicants.
tabling member printed	Lord Turnberg
uin	HL3872
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>We recognise that the NHS Practitioner Health service is valued by many doctors. NHS England is reviewing the service as part of a wider review of its mental health and wellbeing offer to National Health Service staff. It was confirmed on 15 April 2024 that the service will continue to accept new patients from primary and secondary care whilst this review is undertaken over the next 12 months. NHS England will confirm future arrangements once the review has been completed.</p> answering member printed Lord Markham question first answered 22/04/2024 14:47:45 answering member 4948 label Biography information for Lord Markham
tabling member	2537 label Biography information for Lord Turnberg

1701610

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what progress they have made with the proposed amendments to the Part IX of the Drug Tariff, including any impact assessments on the future provision of medical technologies in the UK; how these proposals meet the ambitions of the Life Sciences Vision; and what steps they are taking to ensure that there is sufficient patient choice following the outcome of the consultation.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3841
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3842 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1701611

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3842
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3841 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700782

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to recent research conducted by the Lancet Commission, what steps they plan to take to address the projected surge in prostate cancer cases.
tabling member printed	The Lord Bishop of St Albans
uin	HL3805
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.</p><p> </p><p>In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.</p><p> </p><p>NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.</p><p> </p><p>The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.</p><p> </p><p>Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.</p> answering member printed Lord Markham grouped question UIN HL3806 HL3807 HL3808 question first answered 19/04/2024 13:24:58 answering member 4948 label Biography information for Lord Markham
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1700783

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to expand public awareness campaigns for prostate cancer, following the prediction by the Lancet Commission of a surge in cases.
tabling member printed	The Lord Bishop of St Albans
uin	HL3806
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.</p><p> </p><p>In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.</p><p> </p><p>NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.</p><p> </p><p>The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.</p><p> </p><p>Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.</p> answering member printed Lord Markham grouped question UIN HL3805 HL3807 HL3808 question first answered 19/04/2024 13:24:58 answering member 4948 label Biography information for Lord Markham
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1700784

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the Lancet Commission on prostate cancer, published 4 April 2024.
tabling member printed	The Lord Bishop of St Albans
uin	HL3807
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.</p><p> </p><p>In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.</p><p> </p><p>NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.</p><p> </p><p>The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.</p><p> </p><p>Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.</p> answering member printed Lord Markham grouped question UIN HL3805 HL3806 HL3808 question first answered 19/04/2024 13:24:58 answering member 4948 label Biography information for Lord Markham
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1700785

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, what plans they have to use artificial intelligence systems to support the diagnosis of prostate cancer, as recommended by the Lancet Commission in research published on 4 April.
tabling member printed	The Lord Bishop of St Albans
uin	HL3808
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.</p><p> </p><p>In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.</p><p> </p><p>NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.</p><p> </p><p>The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.</p><p> </p><p>Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.</p> answering member printed Lord Markham grouped question UIN HL3805 HL3806 HL3807 question first answered 19/04/2024 13:24:58 answering member 4948 label Biography information for Lord Markham
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1700786

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer: Ethnic Groups
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to prioritise research into variation of the prevalence of prostate cancer among different ethnic groups.
tabling member printed	The Lord Bishop of St Albans
uin	HL3809
answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department welcomes the recently announced TRANSFORM trial which aims to save thousands of men each year by finding the best way to screen for prostate cancer across all ethnic groups. It will be spread across the United Kingdom, although final decisions on specific locations are yet to be taken. Men will be invited to participate via their general practices. This study, led by Prostate Cancer UK and supported by the Government among others, will also aim to address some of the inequalities that exist in prostate cancer diagnosis today by ensuring that one in ten of the trial participants will be black men, who are three times overrepresented compared to the population of men aged between 45 and 75 years old as based on 2021 census data.</p><p> </p><p>More broadly, the National Institute for Health and Care Research (NIHR) funds research in response to proposals received from scientists and commissioned calls rather than allocating funding to specific disease areas. It welcomes funding applications for research into any aspect of human health, including prostate cancer. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p>In addition, to raise awareness of prostate cancer in this group, Leicester’s Centre for BME Health has developed a toolkit in partnership with the NIHR with guidance on how to start conversations about prostate cancer and overcome barriers to diagnosis.</p> answering member printed Lord Markham question first answered 17/04/2024 16:29:23 answering member 4948 label Biography information for Lord Markham
tabling member	4308 label Biography information for The Lord Bishop of St Albans

1700766

registered interest
date	15/04/2024
answering body	Leader of the House of Lords
answering dept id	92
answering dept short name
answering dept sort name	Leader of the House of Lords
hansard heading	Secretaries of State: Parliamentary Scrutiny
house id	2
legislature	25277 pref label House of Lords
question text	To ask the Leader of the House when they will respond to the Report of the Procedure Committee of the House of Commons Commons scrutiny of Secretaries of State in the House of Lords (1st Report, HC 338).
tabling member printed	Lord Young of Cookham
uin	HL3828
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>The Government responded to the House of Commons Procedure Committee Report Commons scrutiny of Secretaries of State in the House of Lords (1st Report, HC 338) on Wednesday 17th April 2024. A copy of the report can be found on the Procedure Committees website on the link below.</p><p><strong><br><a href="https://committees.parliament.uk/committee/126/procedure-committee/publications/" target="_blank">https://committees.parliament.uk/committee/126/procedure-committee/publications/</a> </strong></p> answering member printed Lord True question first answered 18/04/2024 11:35:16 answering member 4200 label Biography information for Lord True
tabling member	57 label Biography information for Lord Young of Cookham

1700745

registered interest
date	15/04/2024
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Biodiversity
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what progress they have made in reforming incentives, including subsidies for ecologically harmful activities, as required under Target 18 of the Global Biodiversity Framework.
tabling member printed	Lord Randall of Uxbridge
uin	HL3785
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>In May 2024, the UK plans to publish its National Biodiversity Strategy and Action Plan (NBSAP), which will set out national targets and policies for implementing targets in the Global Biodiversity Framework, including Target 18. This will include a target to identify any incentives and subsidies that are harmful to biodiversity. The UK already has a positive story to tell on reforming incentives through our work to deliver the Agricultural Transition. Our Environmental Land Management schemes will incentivise farmers to improve biodiversity, soil health and air and water quality, reduce agricultural emissions, restore peatland, and establish and restore woodlands and forests.</p> answering member printed Lord Benyon question first answered 19/04/2024 13:39:37 answering member 1547 label Biography information for Lord Benyon
tabling member	209 label Biography information for Lord Randall of Uxbridge